Article

Pharmaceutical Technology Europe

Broken biopharm

The engine of biopharmaceutical innovation is broken, according to Eli Lilly's Chairman and CEO, John C. Lechleiter.

The engine of biopharmaceutical innovation is broken, according to Eli Lilly's Chairman and CEO, John C. Lechleiter. Speaking to the City Club of San Diego (CA, USA), which included many business leaders from San Diego's biotech sector, Lechleiter explained that repowering pharmaceutical innovation is an "urgent" need. "At a time when the world desperately needs more new medicines, we're taking too long, spending too much and producing far too little," he said.

He believes that the biotech industry is wasting its potential. Although he acknowledged that several major challenges are facing the industry, such as a loss of trust in product safety and the pressures of the healthcare system, he added that it was a waste of time to complain about these.

Instead, companies should change the way they develop new medicines. In particular, he suggested that collaboration (i.e., working with large and small enterprises, as well as academic and government researchers worldwide) and competency (i.e., taking advantage of advanced scientific tools) could help to boost medical innovation. He also added that patients and improved outcomes should be placed at the center of research from the start of the drug development process.

According to Lechleiter, reinventing biopharm R&D will help regain the public's trust, address the concerns of regulators and demonstrate to policymakers the value that innovative medicines can play.

www.lilly.com

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content